Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help young sarcoma survivors manage pain?

NCT ID NCT07402577

Knowledge-focused Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether a 3-month daily survey program (called ecological momentary assessment) is practical and acceptable for tracking chronic pain and opioid use in adolescent and young adult sarcoma survivors. About 40 survivors aged 12 to 24 at diagnosis, who still have meaningful pain, will use their smartphones to answer daily questions. The goal is to see if this approach works for future research, not to treat pain directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that daily surveys are a practical way to monitor pain and opioid use in young sarcoma survivors, pointing toward better pain management strategies.
What could go wrong
This is a very small, early feasibility study with only 40 participants. It does not test any treatment, so it may not lead to direct improvements in pain or opioid use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients younger than 70 years old who were diagnosed with sarcoma between the ages of 12-24 and have no evidence of disease and/or are enrolled in survivorship care.

Ages

12 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All genders between the ages of 12-24 (inclusive) at sarcoma diagnosis. * Any age \< 70 at the time of study enrollment. * No evidence of disease and/or enrolled in survivorship care. * Clinically meaningful pain related to disease or its treatments at baseline (defined as 3 or greater on a 0-10 Numerical Rating Scale). * Willing to attend the baseline appointment in person. * Access to internet-capable smartphone. * Access to internet on an occasional basis. * Willing and able to complete Ecological Momentary Assessments (EMAs) on internet-capable smartphone for a 3-month period after enrollment. * Ability to understand and provide informed consent/assent. Exclusion Criteria: * \* Currently receiving active cancer-directed therapy. * Unable to read or fluently speak English. * Determined by clinical staff to have preexisting or cancer-associated cognitive impairment that could interfere with study participation. * Acutely suicidal (e.g. intent or plan) or, with unstable medical or psychiatric condition verified by licensed study staff. * Characteristics related to inability to complete the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood sarcoma of soft tissue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Childhood sarcoma of soft tissue Sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.